question,rag_answer,expected_answer,manual_accuracy_score,manual_citation_score,timestamp,assessment_type
Is routine echocardiography recommended for all adults with repaired atrial septal defect without symptoms or residual shunt?,"Based on the provided context from the 2018 AHA/ACC Guidelines on Adult Congenital Heart Disease, the recommendation for routine echocardiography in adults with repaired atrial septal defect (ASD) without symptoms or residual shunt is not explicitly stated. However, the guidelines do provide recommendations for the management of ASD in adults, which may inform the need for echocardiography in this population. According to the guidelines, adults with repaired ASD should undergo regular follow-up with echocardiography to monitor for potential complications, such as residual shunt, right atrial and/or RV enlargement, and impaired functional capacity [1, S4.1.1-10]. In particular, the guidelines suggest that adults with primum ASD, sinus venosus defect, or coronary sinus defect who have impaired functional capacity, right atrial and/or RV enlargement, and net left-to-right shunt sufficiently large to cause physiological sequelae (e.g., Qp:Qs ≥ 1.5:1) without cyanosis at rest or during exercise should be surgically repaired, unless precluded by comorbidities [1, S4.1.1-13]. However, the guidelines also state that the decision to perform echocardiography in adults with repaired ASD without symptoms or residual shunt should be individualized, taking into account the patient's overall clinical status and risk factors for potential complications [2, S4.1.1-9]. Therefore, while routine echocardiography may be recommended for adults with repaired ASD who have symptoms or residual shunt, the guidelines do not provide a clear recommendation for routine echocardiography in asymptomatic adults with repaired ASD without residual shunt. References: [1] S4.1.1-10. Roos-Hesselink JW, Meijboom FJ, Spitaels SEC, et al. Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A prospective follow-up study of 21-33 years. Eur Heart J. 2003;24:190-7. [2] S4.1.1-9. Shah D, Azhar M, Oakley CM, et al. Natural history of secundum atrial septal defect in adults after medical or surgical treatment: a historical prospective study. Br Heart J. 1994;71:224-7. **Conclusion:** The available context does not provide a clear recommendation for routine echocardiography in adults with repaired atrial septal defect without symptoms or residual shunt. The decision to perform echocardiography should be individualized, taking into account the patient's overall clinical status and risk factors for potential complications.","No, routine echocardiography is not indicated in asymptomatic patients with repaired ASD without residual shunt or chamber enlargement.",3,3,20251106_110451,manual
how long should infants and children fast after clear fluids?,"Based on the provided clinical guidelines and medical literature, the recommended fasting duration for infants and children after clear fluids is: * One hour after ingestion of clear fluids for infants and children [Source: 2021 CAS Guidelines to the Practice of Anesthesia.md]
* One hour after ingestion of clear fluids for infants and children [Source: 2025_CAS_Revised_Guidelines.md] It is essential to note that these guidelines apply to all forms of anesthesia, including procedural sedation, and should be modified at the discretion of the physician for patients with conditions that delay gastric emptying. Additionally, the guidelines emphasize the importance of considering the risk of delaying surgery versus the risk of aspiration of gastric contents for emergent or urgent procedures. In the context of pediatric anesthesia, it's also essential to consider the specific needs and conditions of each patient, including their age, weight, and any preexisting medical conditions. The provided sources do not address the specific topic of fluid resuscitation in septic shock or the use of insulin drips in diabetic patients, as discussed in the 2015 ACC_AHA PALS Guidelines.md and Anesthesia Notes.md. Therefore, the answer is based solely on the fasting guidelines for infants and children after clear fluids, as outlined in the 2021 CAS Guidelines to the Practice of Anesthesia.md and 2025_CAS_Revised_Guidelines.md. **Fasting Guidelines for Infants and Children:** * Minimum duration of fasting: one hour after ingestion of clear fluids for infants and children
* Encourage clear fluids (including water, pulp-free juice, complex carbohydrate beverages, and black tea or coffee) up to one hour before elective procedures
* Conditions that delay gastric emptying require individual patient assessment and may modify these fasting guidelines at the discretion of the physician.",one hour,3,3,20251106_110451,manual
what are anesthetic considerations for patients with aortic stenosis,"**Anesthetic Considerations for Patients with Aortic Stenosis** Patients with aortic stenosis (AS) are at high risk of major perioperative cardiac complications during noncardiac surgery. The severity of AS is a critical determinant of the risk of complications, with severe AS associated with a higher risk of mortality and myocardial infarction. **Risk Assessment and Preoperative Evaluation** Preoperative evaluation of patients with AS should include assessment of the severity of AS, presence of symptoms, and coexisting conditions such as coronary artery disease (CAD) and mitral regurgitation (MR). The American College of Cardiology (ACC) and American Heart Association (AHA) guidelines recommend that patients with asymptomatic severe AS should undergo elective noncardiac surgery with appropriate intraoperative and postoperative hemodynamic monitoring [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]. **Anesthetic Management** Management of anesthesia in patients with AS includes prevention of hypotension and any hemodynamic change that will decrease cardiac output. Key considerations include: * **Prevention of Hypotension**: Hypotension can lead to decreased coronary perfusion pressure, arrhythmias, myocardial injury, cardiac failure, and death. Anesthetic agents that can cause vasodilation and hypotension should be avoided or used with caution [Source: 02_Stoelting.md].
* **Maintenance of Cardiac Output**: Patients with AS require maintenance of cardiac output to prevent decreased coronary perfusion pressure and cardiac ischemia. Anesthetic agents that can cause vasodilation and tachycardia should be avoided [Source: 02_Stoelting.md].
* **Avoidance of Tachycardia**: Tachycardia can lead to decreased cardiac output and increased myocardial oxygen demand. Anesthetic agents that can cause tachycardia should be avoided or used with caution [Source: 02_Stoelting.md].
* **Use of Vasopressors**: Vasopressors may be necessary to maintain blood pressure and cardiac output in patients with AS. However, their use should be judicious and monitored closely to avoid excessive vasopressor levels that can lead to cardiac ischemia and other complications [Source: 02_Stoelting.md]. **Postoperative Care** Postoperative care of patients with AS should include close monitoring of hemodynamics, cardiac output, and cardiac biomarkers. Patients with AS are at high risk of cardiac complications, including myocardial infarction, cardiac failure, and arrhythmias. Close monitoring and prompt intervention are essential to prevent these complications. **Conclusion** Patients with aortic stenosis are at high risk of major perioperative cardiac complications during noncardiac surgery. Management of anesthesia in these patients requires careful consideration of the severity of AS, presence of symptoms, and coexisting conditions. Prevention of hypotension, maintenance of cardiac output, avoidance of tachycardia, and use of vasopressors as necessary are essential to prevent cardiac complications. **References** [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]
[Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md]
[Source: 02_Stoelting.md]","maintain normal sinus rhythm, avoid bradycardia or tachycardia, avoid hypotension, optimize intravascular volume",3,3,20251106_110451,manual
Should vitamin K be co-administered with PCC?,"Based on the provided context and relevant clinical guidelines, it is recommended to co-administer vitamin K with Prothrombin Complex Concentrate (PCC) for the rapid reversal of vitamin K antagonists, especially in the context of major or life-threatening bleeding. According to [Source: Blood components updated V2 final.md], vitamin K is essential for the synthesis of clotting factors II, VII, IX, and X, and their depletion can occur in the presence of vitamin K deficiency. The text suggests that administering PCC may not be sufficient without vitamin K, as the short half-life of factor VII (6 hours) necessitates the administration of vitamin K to maintain reversal. Furthermore, [Source: ASRA Guidelines 2025.md] notes that when there is life-threatening bleeding, recombinant activated factor VIIa (rFVIIa), three-factor PCC, or four-factor PCC can be given. However, it is crucial to administer vitamin K to maintain reversal, even if other agents are used. Additionally, [Source: Anesthesia Notes.md] highlights the importance of vitamin K in the synthesis of clotting factors and its deficiency can lead to prolongation of the prothrombin time (PT). Vitamin K should be administered in conjunction with other agents to maintain reversal and prevent hypercoagulability. The 2014 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease [Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md] also emphasizes the importance of vitamin K administration in the context of anticoagulation reversal. According to the guideline, high-dose vitamin K should not be given routinely, but 1 mg to 2.5 mg of oral vitamin K1 (phytonadione) may be administered in addition to holding VKA therapy in patients with an INR >10 who are not bleeding. In conclusion, based on the provided context and clinical guidelines, it is recommended to co-administer vitamin K with PCC for the rapid reversal of vitamin K antagonists, especially in the context of major or life-threatening bleeding. Key Takeaways: * Vitamin K is essential for the synthesis of clotting factors II, VII, IX, and X.
* Administering PCC may not be sufficient without vitamin K, as the short half-life of factor VII necessitates the administration of vitamin K.
* Vitamin K should be administered in conjunction with other agents to maintain reversal and prevent hypercoagulability.
* High-dose vitamin K should not be given routinely, but 1 mg to 2.5 mg of oral vitamin K1 (phytonadione) may be administered in addition to holding VKA therapy in patients with an INR >10 who are not bleeding. References: [Source: Blood components updated V2 final.md]
[49]
[50]
[51] [Source: ASRA Guidelines 2025.md]
216
227
228
229
230 [Source: Anesthesia Notes.md]
[Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md]
124
Page 124 of 235
Downloaded from http://circ.ahajournals.org/ by guest on March 3, 2014
Figure 6. Anticoagulation for Prosthetic Valves
(600)
(603)","Yes, 5–10mg intravenous vitamin K should be given with PCC to maintain correction.",3,3,20251106_110451,manual
is preoperative echocardiography recommended for patients with suspected moderate or severe valvular disease?,"Based on the provided context from the clinical guidelines and medical literature, the recommendation for preoperative echocardiography in patients with suspected moderate or severe valvular disease is as follows: **For patients with suspected moderate or severe valvular disease:** * The 2017 CCS Guidelines on Cardiac Risk for Non-Cardiac Surgery [1] recommend against routinely performing preoperative resting echocardiography to enhance perioperative cardiac risk estimation (Strong Recommendation; Low Quality Evidence).
* However, if a patient has a clinical examination suggesting an undiagnosed severe obstructive intracardiac abnormality (e.g., aortic stenosis, mitral stenosis, hypertrophic obstructive cardiomyopathy) or severe pulmonary hypertension, urgent echocardiography should be obtained before surgery to inform the anesthesiologist, surgeon, and medical team of the type and degree of disease [1]. **For patients with suspected moderate or severe valvular disease undergoing non-cardiac surgery:** * The 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery [2] recommends that patients with suspected valvular heart disease should undergo echocardiography to quantify the severity of stenosis or regurgitation, calculate systolic function, and estimate right heart pressures.
* Evaluation for concurrent coronary artery disease (CAD) is also warranted, with electrocardiography exercise testing, stress echocardiographic or nuclear imaging study, or coronary angiography, as appropriate [2]. **Specific recommendations for aortic stenosis:** * The 2014 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease [3] recommends that patients with asymptomatic severe aortic stenosis may undergo elevated-risk elective non-cardiac surgery with appropriate intraoperative and postoperative hemodynamic monitoring (Class IIa, Level of Evidence: B).
* The 2021 CAS Guidelines to the Practice of Anesthesia [4] recommend that resting echocardiography may be considered if clinical assessment suggests undiagnosed severe obstructive intra-cardiac abnormality, cardiomyopathy, or severe pulmonary hypertension. **Conclusion:** In patients with suspected moderate or severe valvular disease, preoperative echocardiography may be recommended in specific clinical scenarios, such as undiagnosed severe obstructive intracardiac abnormalities or severe pulmonary hypertension. However, routine preoperative resting echocardiography is not recommended to enhance perioperative cardiac risk estimation. References: [1] Duceppe et al. Perioperative Cardiac Risk Assessment & Management. 2017 CCS Guidelines on Cardiac Risk for Non-Cardiac Surgery.md [2] Fleisher et al. 2014 ACC/AHA Perioperative Guideline. 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md [3] Lombard JT, Selzer A. Valvular aortic stenosis. A clinical and hemodynamic profile of patients. Ann Intern Med. 1987;106:292-8. [Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md] [4] 2021 CAS Guidelines to the Practice of Anesthesia.md","Yes, echocardiography is recommended for patients with suspected moderate or greater valvular stenosis or regurgitation.",3,3,20251106_110451,manual
How should peri-operative anticoagulants be managed?,"**Peri-operative Anticoagulants Management** The peri-operative management of anticoagulants involves assessing the bleeding and thrombosis risk, as well as renal function, to determine the optimal management strategy. **Direct Oral Anticoagulants (DOACs)** For patients taking DOACs (e.g., apixaban, rivaroxaban, edoxaban), the suggested algorithm for peri-operative management is as follows [Source: Blood components updated V2 final.md]: - Assess bleeding risk: - Low: Duration of DOAC cessation before surgery: 24-48 hours - High: Duration of DOAC cessation before surgery: 48-72 hours
- Assess thrombosis risk: - Low: Prophylactic LMWH 6-8 hours after surgery - High: Continue LMWH in the interim, and delay DOAC for 48 hours if concerns regarding bleeding
- Resume DOAC: - 6-8 hours after surgery for low thrombosis risk - 48-72 hours after surgery for high thrombosis risk **Warfarin** For patients taking warfarin, the peri-operative management involves bridging anticoagulation [Source: 2013 Thrombosis Canada Wafarin Bridging.md]: - Indications: - No strong evidence-based indications for bridging anticoagulation - Bridging is suggested in high-risk patients, not suggested in low-risk patients, and optional in intermediate-risk patients
- Dosing: - Subcutaneous (SC) therapeutic-dose LMWH: enoxaparin 1 mg/kg twice daily or 1.5 mg/kg once daily; dalteparin 100 IU/kg twice daily or 200 IU/kg once daily; or tinzaparin 175 IU/kg once daily - Intravenous (IV) unfractionated heparin (UFH) to achieve a therapeutic activated partial thromboplastin time (aPTT) - SC low-dose LMWH in patients with a high-bleeding-risk surgery/procedure: enoxaparin 40 mg once daily; dalteparin 5000 IU once daily; or tinzaparin 4500 IU once daily
- Monitoring: - No need for laboratory monitoring of bridging with SC LMWH - Monitoring is required for bridging with IV UFH (aPTT) **Reversal of Anticoagulation** For patients requiring reversal of anticoagulation, the following options are available [Source: Blood components updated V2 final.md]: - Idarucizumab: a specific antagonist to dabigatran, which can be used to reverse dabigatran effect rapidly
- Andexanet alfa: treatment of severe gastrointestinal haemorrhage and limitation of haematoma size in intracranial haemorrhage
- Ciraparantag: a newer drug in development that binds noncovalently to heparin, LMWH, and DOACs, which is undergoing early phase trials **Important Considerations** - Patients undergoing surgery where some degree of anticoagulation is required (e.g., requirement for cardiopulmonary bypass and non-cardiac vascular surgery) should not use andexanet alfa
- The use of andexanet alfa should be avoided in patients with a history of cardiac surgery or those with a mechanical heart valve
- The management of anticoagulation in patients undergoing surgery requires careful consideration of the bleeding and thrombosis risk, as well as renal function **References** [Source: Blood components updated V2 final.md]
Shah et al. | Peri-operative use of blood components and their alternatives
[13652044, 0, Downloaded from https:/associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.16542 by Test, Wiley Online Library on [17/01/2025]. See the Terms and Conditions (https:/onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA article] [Source: 2013 Thrombosis Canada Wafarin Bridging.md]
PERI-OPERATIVE MANAGEMENT OF PATIENTS WHO ARE RECEIVING WARFARIN
[Target Audience: All Canadian health care professionals.]
[Objective: To provide an approach to the peri-operative management of warfarin-treated patients and the need for bridging anticoagulation during warfarin interruption.] [Source: 2018 ASRA Regional Anesthesia and Antithrombotics.md]
This table summarizes the clinical courses and outcomes of patients undergoing various surgical procedures with different anticoagulant regimens.
[Each entry provides detailed patient information and outcomes related to the use of regional anesthesia.] [Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md]
Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506-11.
Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA. 1978;239:738-9.
Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation. 2009;119:2920-7.
Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J. 2009;30:2769-812.
Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Erratum in: Chest. 2012 Apr; 141(4):1129. Chest. 2012;141:e326S-e350S.
Pernod G, Godier A, Gozalo C, et al. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res. 2010;126:e167e174.
Weibert RT, Le DT, Kayser SR, et al. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med. 1997;126:959-62.
Yiu KH, Siu CW, Jim MH, et al. Comparison of the efficacy and safety profiles of intravenous vitamin K and fresh frozen plasma as treatment of warfarin-related over-anticoagulation in patients with mechanical heart valves. Am J Cardiol. 2006;97:409-11.
Genewein U, Haeberli A, Straub PW, et al. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol. 1996;92:479-85.",They should be managed to balance the risk of bleeding with the risk of thrombosis.,3,3,20251106_110451,manual
when should beta (β) blockers be avoided in the setting of an MI,"**Beta-Blocker Therapy in the Setting of Myocardial Infarction (MI)** Beta-blockers are a cornerstone in the management of patients with myocardial infarction (MI), and their use is well-established in clinical guidelines. However, there are specific situations where beta-blocker therapy should be avoided. **Avoid Starting Beta-Blockers on the Day of Surgery** According to the 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery, beta-blocker therapy should not be started on the day of surgery [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]. This is because acute administration of high-dose beta-blockers in high-risk populations may be harmful (Class III: Harm) [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]. **Preoperative Beta-Blocker Initiation** The guideline also recommends that beta-blockers be initiated more than 1 day before surgery to assess safety and tolerability (Class IIb) [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]. Starting beta-blockers ≤ 1 day before surgery may be ineffective and potentially harmful (Class III: Harm) [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]. **Specific Situations Where Beta-Blockers Should Be Avoided** * In patients with multiple risk factors or reversible ischemia on preoperative testing, beta-blockers should be initiated at least 1 week before elective surgery [Source: 01_Stoelting.md].
* In patients with a compelling long-term indication for beta-blocker therapy but no other RCRI risk factors, initiating beta blockers in the perioperative setting as an approach to reduce perioperative risk is of uncertain benefit (Class IIb) [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md].
* ACE inhibitors and ARBs should not be given to pregnant patients with valve stenosis (Class III: Harm) [Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md]. **Conclusion** In summary, beta-blocker therapy should not be started on the day of surgery, and beta-blockers should be initiated more than 1 day before surgery to assess safety and tolerability. Specific situations where beta-blockers should be avoided include patients with multiple risk factors or reversible ischemia on preoperative testing, patients with a compelling long-term indication for beta-blocker therapy but no other RCRI risk factors, and pregnant patients with valve stenosis.","they should not be given to patients in heart failure, who are in a low cardiac output state, or at risk of cardiomyopathy",3,3,20251106_110451,manual
what is the mortality rate of patients with STEMI who undergo aggressive reperfusion versus those that don't,"Based on the provided context and clinical guidelines, I will attempt to answer the question regarding the mortality rate of patients with STEMI who undergo aggressive reperfusion versus those that don't. However, I must note that the context does not provide explicit information on STEMI (ST-Elevation Myocardial Infarction) or aggressive reperfusion. The context primarily discusses perioperative risks, cardiac risk assessment, and outcomes in non-cardiac surgery patients. Given the constraints of the provided context and the allowed sources, I must rely on the information available. The closest relevant information is related to cardiac risk assessment and outcomes in non-cardiac surgery patients. According to the 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery, patients with a previous myocardial infarction, heart failure, or stroke have a higher risk of perioperative cardiac complications (Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md). Regarding the mortality rate of patients with STEMI who undergo aggressive reperfusion versus those that don't, the context does not provide specific information. However, I can provide some general information on the outcomes of STEMI patients who undergo reperfusion therapy. Aggressive reperfusion therapy for STEMI has been shown to improve outcomes and reduce mortality in several studies (Source: [Source filename not provided, but based on related literature]). A meta-analysis of 11 trials found that early reperfusion therapy (within 12 hours of symptom onset) was associated with a significant reduction in mortality compared to delayed reperfusion therapy (Source: [Source filename not provided, but based on related literature]). Another study found that patients who underwent primary percutaneous coronary intervention (PCI) for STEMI had a lower mortality rate compared to those who received thrombolysis (Source: [Source filename not provided, but based on related literature]). However, it is essential to note that these studies are not directly related to the context provided, and the mortality rates mentioned are not specific to STEMI patients undergoing aggressive reperfusion versus those that don't. In conclusion, while the context does not provide explicit information on STEMI or aggressive reperfusion, the available literature suggests that reperfusion therapy for STEMI can improve outcomes and reduce mortality. However, the specific mortality rates of STEMI patients who undergo aggressive reperfusion versus those that don't cannot be determined from the provided context. References: * 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md (provided context)
* [Source filename not provided, but based on related literature] (meta-analysis of 11 trials)
* [Source filename not provided, but based on related literature] (study comparing primary PCI and thrombolysis for STEMI) Please note that the references provided are not actual citations from the context, but rather examples of related literature that may be relevant to the topic.",with aggressive reperfusion the mortality is 6.5% and without from between 15 - 20%,3,3,20251106_110451,manual
is routine 12-lead electrocardiography recommended for asymptomatic patients undergoing low-risk surgery?,"**Routine 12-Lead Electrocardiography for Asymptomatic Patients Undergoing Low-Risk Surgery** Based on the provided clinical guidelines and medical literature, routine preoperative resting 12-lead electrocardiography (ECG) is not recommended for asymptomatic patients undergoing low-risk surgery. * According to the 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery, routine preoperative resting 12-lead ECG is not useful for asymptomatic patients undergoing low-risk surgical procedures. * Additionally, the guideline recommends that preoperative resting 12-lead ECG may be considered for asymptomatic patients, except for low-risk surgery, which is classified as a Class IIb recommendation. It is essential to note that the guideline also suggests that the prognostic significance of electrocardiographic abnormalities increases with patient age and with risk factors for coronary heart disease. However, a standard age or risk factor cutoff for use of preoperative electrocardiographic testing has not been defined. In summary, based on the provided literature and guidelines, routine 12-lead electrocardiography is not recommended for asymptomatic patients undergoing low-risk surgery. **Key Recommendations:** * Routine preoperative resting 12-lead ECG is not useful for asymptomatic patients undergoing low-risk surgical procedures. * Preoperative resting 12-lead ECG may be considered for asymptomatic patients, except for low-risk surgery, which is classified as a Class IIb recommendation. **References:** * 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md
* Gold BS, Young ML, Kinman JL, et al. The utility of preoperative electrocardiograms in the ambulatory surgical patient. Arch Intern Med. 1992;152:301-5.
* Noordzij PG, Boersma E, Bax JJ, et al. Prognostic value of routine preoperative electrocardiography in patients undergoing noncardiac surgery. Am J Cardiol. 2006;97:1103-6.
* Biteker M, Duman D, Tekkesin AI. Predictive value of preoperative electrocardiography for perioperative cardiovascular outcomes in patients undergoing noncardiac, nonvascular surgery. Clin Cardiol. 2012;35:494-9.
* Liu LL, Dzankic S, Leung JM. Preoperative electrocardiogram abnormalities do not predict postoperative cardiac complications in geriatric surgical patients. J Am Geriatr Soc. 2002;50:1186-91.
* Turnbull JM, Buck C. The value of preoperative screening investigations in otherwise healthy individuals. Arch Intern Med. 1987;147:1101-5.
* Kontos MC, Brath LK, Akosah KO, et al. Cardiac complications in noncardiac surgery: relative value of resting two-dimensional echocardiography and dipyridamole thallium imaging. Am Heart J. 1996;132:559-66.
* Rohde LE, Polanczyk CA, Goldman L, et al. Usefulness of transthoracic echocardiography as a tool for risk stratification of patients undergoing major noncardiac surgery. Am J Cardiol. 2001;87:505-9.
* Halm EA, Browner WS, Tubau JF, et al. Echocardiography for assessing cardiac risk in patients having noncardiac surgery. Study of Perioperative Ischemia Research Group. Ann Intern Med. 1996;125:433-41.
* Baron JF, Mundler O, Bertrand M, et al. Dipyridamole-thallium scintigraphy and gated radionuclide angiography to assess cardiac risk before abdominal aortic surgery. N Engl J Med. 1994;330:663-9.
* Foster ED, Davis KB, Carpenter JA, et al. Risk of noncardiac operation in patients with defined coronary disease: The Coronary Artery Surgery Study (CASS) registry experience. Ann Thorac Surg. 1986;41:42-50.","No, routine ECG is not recommended for asymptomatic patients undergoing low-risk procedures.",3,3,20251106_110451,manual
What is the recommended oxygen saturation (SaO2) during one lung ventilation (OLV)?,"To answer the question regarding the recommended oxygen saturation (SaO2) during one lung ventilation (OLV), we need to consider the relevant information from the provided sources. [Source: step by step management of onelung ventilation CJA 2014.md] The provided source suggests the following recommendations for oxygen saturation during OLV: - A target SpO2 of 92-96% should be aimed for during OLV.
- The initial FIO2 should be 0.5-0.8, which can be titrated to the minimum required to achieve the target SpO2. [Source: wk_3b_slinger_06_olv_management.md] This source also emphasizes the importance of maintaining adequate oxygenation during OLV, stating that atelectasis in the non-operative lung must be avoided as it worsens the already high shunt fraction from lung isolation. [Source: 09_Stoelting.md] While this source primarily focuses on oxygen supplementation post-tracheal extubation, it does provide information about the significance of oxygen exchange and arterial oxygenation in the context of lung function. It highlights that significant desaturation of arterial blood occurs when the PaO2 is less than 60 mm Hg. [Source: One Lung Ventilation.md] This source discusses various factors influencing ventilation during OLV, including respiratory rate and mode of ventilation. However, it does not provide specific recommendations for oxygen saturation during OLV. Considering the above points, the most relevant information comes from [Source: step by step management of onelung ventilation CJA 2014.md], which recommends a target SpO2 of 92-96% during OLV. In conclusion, the recommended oxygen saturation (SaO2) during one lung ventilation (OLV) is a target SpO2 of 92-96%, with an initial FIO2 of 0.5-0.8 that can be titrated to the minimum required to achieve the target SpO2. **Important Patient Safety Consideration:** - Maintaining adequate oxygenation during OLV is crucial to prevent hypoxemia and associated complications.
- Regular monitoring of oxygen saturation and titration of FIO2 as needed are essential to achieve optimal oxygenation while minimizing the risk of oxygen toxicity. **Critical Clinical Recommendations:** - Target SpO2 of 92-96% during OLV
- Initial FIO2 of 0.5-0.8, titrated to the minimum required to achieve the target SpO2",92-96%,3,3,20251106_110451,manual
what are common causes of secondary hypertension?,"**Common Causes of Secondary Hypertension** Secondary hypertension accounts for fewer than 5% of all cases of systemic hypertension. According to the provided clinical guidelines and medical literature [Source: 05_Stoelting.md], the most common cause of secondary hypertension is renal artery stenosis leading to renovascular hypertension. **Common Causes of Secondary Hypertension with Notable Signs and Symptoms (Table 5-2)** The following are common causes of secondary hypertension with their notable signs and symptoms, as listed in Table 5-2: * **Renovascular disease**: + Epigastric or abdominal bruit + Severe hypertension in young patients + Laboratory evaluation: MRA, aortography, duplex ultrasonography, CT angiography
* **Hyperaldosteronism**: + Fatigue + Weakness + Headache + Paresthesia + Nocturnal polyuria and polydipsia + Laboratory evaluation: Urinary potassium, serum potassium, plasma renin, plasma aldosterone
* **Aortic coarctation**: + Elevated blood pressure in upper limbs relative to lower limbs + Weak femoral pulses + Laboratory evaluation: Aortography, echocardiography, MRI or CT
* **Pheochromocytoma**: + Episodic headache, palpitations, and diaphoresis + Paroxysmal hypertension + Laboratory evaluation: Plasma metanephrines, urinary catecholamines, spot urine metanephrines, adrenal CT/MRI scan
* **Cushing's syndrome**: + Truncal obesity + Proximal muscle weakness + Purple striae + Moon facies + Hirsutism + Laboratory evaluation: Dexamethasone suppression test, urinary cortisol, adrenal CT scan, glucose tolerance test **Other Causes of Secondary Hypertension (Table 5-3)** Other causes of secondary hypertension include: * **Renal disorders**: + Renal transplantation + Renin-secreting tumors
* **Endocrine**: + Acromegaly + Hyperparathyroidism
* **Obstructive sleep apnea**
* **Postoperative hypertension**
* **Neurologic disorders**: + Increased intracranial pressure + Spinal cord injury + Guillain-Barré syndrome + Dysautonomia
* **Drugs**: + Glucocorticoids + Mineralocorticoids + Cyclosporine + Sympathomimetics + Tyramine and monoamine oxidase inhibitors
* **Sudden withdrawal from antihypertensive drug therapy (central acting and β -adrenergic antagonists)** **Compelling Indications for Specific Classes of Antihypertensive Drugs (Table 5-4)** The following are compelling indications for specific classes of antihypertensive drugs, as listed in Table 5-4: * **Previous myocardial infarction**: ACE inhibitor, aldosterone antagonist, β -blocker
* **Heart failure**: ACE inhibitor, aldosterone antagonist, ARB, β -blocker, diuretic
* **High risk of coronary artery disease**: ACE inhibitor, β -blocker, calcium channel blocker, diuretic
* **Diabetes**: ACE inhibitor, ARB, β -blocker, calcium channel blocker, diuretic
* **Chronic kidney disease**: ACE inhibitor, ARB
* **Recurrent stroke prevention**: ACE inhibitor, diuretic **Commonly Used Antihypertensive Drugs (Table 5-5)** The following are commonly used antihypertensive drugs, as listed in Table 5-5: * **ACE inhibitors**
* **Aldosterone antagonists**
* **ARBs**
* **β -Blockers**
* **Calcium channel blockers**
* **Diuretics** **Primary Hyperaldosteronism (Conn's Syndrome)** Primary hyperaldosteronism (Conn's syndrome) is present when there is excess secretion of aldosterone from a functional tumor (aldosteronoma) that acts independently of a physiologic stimulus [Source: 19_Stoelting.md]. Clinical signs and symptoms of primary aldosteronism are nonspecific and may reflect systemic hypertension (headache) or hypokalemia (polyuria, nocturia, skeletal muscle cramps, skeletal muscle weakness). **Diagnosis of Primary Hyperaldosteronism** The diagnosis of primary hyperaldosteronism is suggested by: * **Increased urinary excretion of potassium** (more than 30 mEq/day) in the presence of hypokalemia
* **Hypokalemic metabolic alkalosis**
* **Systemic hypertension** (diastolic blood pressure is often 100 to 125 mm Hg)
* **Laboratory evaluation**: Urinary potassium, serum potassium, plasma renin, plasma aldosterone, adrenal CT/MRI scan. Note: This answer is based on the provided clinical guidelines and medical literature and should be verified against current clinical guidelines and protocols.","renovascular disease, hyperaldosteronism, aortic coarctation, pheochromocytoma, cushing's syndrome, pregnancy induced hypertension",3,3,20251106_110451,manual
should statin therapy be continued perioperatively in patients undergoing noncardiac surgery?,"Based on the provided clinical guidelines and medical literature, the recommendation for continuing statin therapy perioperatively in patients undergoing noncardiac surgery is as follows: **Recommendation:** * Continue statin therapy perioperatively in patients who are receiving chronic statin therapy (Strong Recommendation; Moderate-Quality Evidence). [Source: 2017 CCS Guidelines on Cardiac Risk for Non-Cardiac Surgery.md]
* Continue statin therapy in patients currently taking statins and scheduled for noncardiac surgery. (Class I, Level of Evidence: B) [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]
* Perioperative initiation of statin use is reasonable in patients undergoing vascular surgery. (Class IIa, Level of Evidence: B) [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md] **Rationale:** * The 2017 CCS Guidelines on Cardiac Risk for Non-Cardiac Surgery.md state that the evidence is too weak to support a recommendation for initiating statin therapy before noncardiac surgery, but the panel recommended continuing statin therapy perioperatively in patients who are receiving chronic statin therapy. [Source: 2017 CCS Guidelines on Cardiac Risk for Non-Cardiac Surgery.md]
* The 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md recommends continuing statin therapy in patients currently taking statins and scheduled for noncardiac surgery (Class I, Level of Evidence: B). [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]
* The guideline also recommends perioperative initiation of statin use in patients undergoing vascular surgery (Class IIa, Level of Evidence: B). [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md] **Evidence:** * A systematic review and meta-analysis of 3 trials (total of 178 patients) found that perioperative administration of a statin had no effect on all-cause mortality, cardiac mortality, and nonfatal myocardial infarction in patients undergoing vascular surgery. * A randomized controlled trial (RCT) included 550 patients who were admitted for an urgent/emergent surgery and had been taking chronic statin therapy. Patients were randomized to receive rosuvastatin 20 mg or placebo 2 hours before surgery. At 30 days, 10 patients (3.6%) in the rosuvastatin group and 22 patients (8.0%) in the placebo group suffered a myocardial infarction (P < 0.03). [Source: 2017 CCS Guidelines on Cardiac Risk for Non-Cardiac Surgery.md]
* A Cochrane analysis of 3 studies (total of 178 participants) found that statin therapy was associated with a reduced risk of myocardial infarction and cardiac mortality in patients undergoing vascular surgery. **Conclusion:** Based on the provided clinical guidelines and medical literature, the recommendation for continuing statin therapy perioperatively in patients undergoing noncardiac surgery is to continue statin therapy in patients who are receiving chronic statin therapy, and to consider perioperative initiation of statin use in patients undergoing vascular surgery.","Yes, statin therapy should be continued in the perioperative period.",3,3,20251106_110451,manual
Is prehospital tranexamic acid beneficial within 3 hours of trauma?,"Based on the provided context, the use of prehospital tranexamic acid within 3 hours of trauma is supported by clinical guidelines and medical literature. According to the CRASH-3 trial, tranexamic acid has been shown to reduce death, disability, and vascular occlusive events in patients with acute traumatic brain injury . A multicenter study in England found that prehospital tranexamic acid was beneficial in the treatment of major traumatic hemorrhage, with a significant reduction in mortality . The use of tranexamic acid in prehospital settings is also supported by the British Committee for Standards in Haematology (BCSH), which recommends the use of tranexamic acid for patients with major trauma and significant bleeding ]. However, it is essential to note that the use of tranexamic acid should be cautious in patients with massive haematuria (if risk of ureteric obstruction), patients on oral contraceptive pills (risk of thrombosis), and is contraindicated in disseminated intravascular coagulation ]. In summary, the evidence suggests that prehospital tranexamic acid within 3 hours of trauma is beneficial in reducing mortality and morbidity in patients with acute traumatic brain injury and major traumatic hemorrhage. However, its use should be cautious and contraindicated in specific patient populations. **Key Recommendations:** * Prehospital tranexamic acid should be considered in patients with major traumatic hemorrhage and acute traumatic brain injury.
* The use of tranexamic acid should be cautious in patients with massive haematuria (if risk of ureteric obstruction), patients on oral contraceptive pills (risk of thrombosis), and is contraindicated in disseminated intravascular coagulation.
* Patients should be carefully selected for tranexamic acid treatment based on their individual clinical condition and risk factors. **References:** * CRASH-3 Trial Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019; 394:1713-23. https://doi.org/10.1016/s0140-6736(19) 32233-0.
* Gruen RL, Mitra B, Bernard SA, et al. Prehospital tranexamic acid for severe trauma. N Engl J Med 2023; 389:127-36. https://doi.org/10.1056/nejmoa2215457.
* [Source: Blood components updated V2 final.md]","Yes, tranexamic acid within 3 hours reduces mortality in bleeding trauma patients.",3,3,20251106_110451,manual
is sodium bicarbonate therapy recommended in sepsis?,"**Sodium Bicarbonate Therapy in Sepsis** The available context provides evidence-based recommendations on the use of sodium bicarbonate therapy in sepsis. **Recommendations:** * For adults with septic shock and hypoperfusion-induced lactic acidemia, the Surviving Sepsis Campaign suggests against using sodium bicarbonate therapy to improve hemodynamics or to reduce vasopressor requirements. [Source: 2021 Surviving Sepsis Guidelines Updates.md]
* For adults with septic shock, severe metabolic acidemia (pH ≤ 7.2) and acute kidney injury (AKIN score 2 or 3), the Surviving Sepsis Campaign suggests using sodium bicarbonate therapy. [Source: 2021 Surviving Sepsis Guidelines Updates.md]
* In general, the administration of sodium bicarbonate is not necessary unless the acidosis is severe enough to overcome the compensatory mechanisms (pH < 7.1 or 7.2 or plasma bicarbonate concentration of 8 mEq/L or less). [Source: Anesthesia Notes.md] **Dosing and Administration:** * The bicarbonate dose is based on the calculated deficit determined from arterial blood gas (ABG) measurements, as well as on the patient's age, weight, and clinical condition. [Source: Anesthesia Notes.md]
* The recommended formula for calculating the bicarbonate dose is: NaHCO3 (mEq) = 0.3 x wt (kg) x base deficit (mEq/L) [Source: Anesthesia Notes.md]
* Only ½ of the calculated deficit should be replaced at one time, and fractional doses may be repeated as necessary. [Source: Anesthesia Notes.md] **Complications:** * Chemical cellulitis and extravasation of NaHCO3 [Source: Anesthesia Notes.md]
* Metabolic alkalosis, which can lead to: + L shift of the oxyhemoglobin dissociation curve and subsequent impairment of oxygen release [Source: Anesthesia Notes.md] + Hyperirritability or tetany [Source: Anesthesia Notes.md] + Hypokalemia, which can occur due to the exchange of K+ for H+ in the tissues in an attempt to offset the metabolic alkalosis [Source: Anesthesia Notes.md] **Special Considerations:** * During cardiac arrest, sodium bicarbonate may exacerbate acidosis, and hypertonic solutions may cause a decrease in coronary perfusion pressure. [Source: Anesthesia Notes.md]
* Sodium bicarbonate and hydrogen ions do not readily cross the blood-brain barrier, and the concentration of bicarbonate in cerebrospinal fluid is similar to that in blood. [Source: Anesthesia Notes.md] **Conclusion:** Sodium bicarbonate therapy in sepsis should be used with caution and only in specific cases, such as severe metabolic acidemia (pH ≤ 7.2) and acute kidney injury (AKIN score 2 or 3). The dose and administration should be carefully calculated based on the patient's age, weight, and clinical condition.","yes, in adults with septic shock and hypoperfusion induced lactic acidemia, sodium bicarbonate can be used to improve hemodynamics or to reduce vasopressor requirements",3,3,20251106_110451,manual
what are the commong intravenous drug therapies for rate control with atrial flutter,"**Intravenous Drug Therapies for Rate Control with Atrial Flutter** According to the clinical guidelines and medical literature, the common intravenous drug therapies for rate control with atrial flutter include: * **Amiodarone**: A useful agent for controlling the ventricular rate and may aid in restoring or maintaining sinus rhythm [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]
* **Diltiazem**: A nondihydropyridine calcium channel blocker that can help control the ventricular rate [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]
* **Verapamil**: A nondihydropyridine calcium channel blocker that can help control the ventricular rate, but may precipitate or worsen heart failure in patients with depressed ejection fraction or clinical heart failure [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]
* **Procainamide**: May be considered for patients with 1:1 conduction and a ventricular rate of 300 beats per minute or faster, as reentry is the most likely mechanism [Source: 04_Stoelting.md] **Important Considerations** * Ventricular rate control should be the initial goal of therapy to prevent deterioration in AV conduction from 2:1 to 1:1, which can cause severe hemodynamic instability [Source: 04_Stoelting.md]
* Intravenous amiodarone, diltiazem, or verapamil may be attempted if vital signs are stable, but the choice of pharmacologic agent depends on the co-existing medical conditions of the patient [Source: 04_Stoelting.md]
* Patients with atrial flutter lasting longer than 48 hours should receive anticoagulant therapy and undergo transesophageal echocardiography for the presence of an atrial thrombus before any attempt at cardioversion is made [Source: 04_Stoelting.md] **Perioperative Management** * If atrial flutter occurs before induction of anesthesia, surgery should be postponed if possible until control of the dysrhythmia has been achieved [Source: 04_Stoelting.md]
* Management of atrial flutter occurring during anesthesia or surgery depends on the hemodynamic stability of the patient, and cardioversion may be required if the atrial flutter is hemodynamically significant [Source: 04_Stoelting.md] **References** [Source: 04_Stoelting.md]
[Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]","amiodarone, diltiazem, or verapamil",3,3,20251106_110451,manual
What is the recommended restrictive transfusion threshold in ICU patients?,"Based on the provided clinical guidelines and medical literature, the recommended restrictive transfusion threshold in ICU patients is a hemoglobin concentration of 70 g/L. This recommendation is based on moderate-quality evidence and is specifically stated in the 2021 Surviving Sepsis Guidelines. [Source: 2021 Surviving Sepsis Guidelines.md] A restrictive transfusion strategy is recommended for adults with sepsis or septic shock, with a hemoglobin concentration transfusion trigger of 70 g/L. This approach is supported by two randomized controlled trials (TRISS and TRICC), which showed similar outcomes in patients with a hemoglobin concentration of 70 g/L compared to those with a higher hemoglobin concentration. [Source: 2021 Surviving Sepsis Guidelines.md] In children over 3 months of age, a restrictive threshold of < 70 g/L is also recommended for RBC transfusion. However, higher transfusion thresholds are often applied to neonates and children with congenital heart disease. [Source: Blood components updated V2 final.md] It is essential to note that RBC transfusion should not be guided by hemoglobin concentration alone, but rather by assessment of a patient's overall clinical status and consideration of extenuating circumstances such as acute myocardial ischemia, severe hypoxemia, or acute hemorrhage. [Source: 2021 Surviving Sepsis Guidelines.md] In summary, the recommended restrictive transfusion threshold in ICU patients is a hemoglobin concentration of 70 g/L, based on moderate-quality evidence from randomized controlled trials. This threshold should be used in conjunction with assessment of a patient's overall clinical status and consideration of extenuating circumstances. **Key Recommendations:** * For adults with sepsis or septic shock, use a restrictive transfusion strategy with a hemoglobin concentration transfusion trigger of 70 g/L.
* In children over 3 months of age, use a restrictive threshold of < 70 g/L for RBC transfusion.
* Consider higher transfusion thresholds in neonates and children with congenital heart disease.
* RBC transfusion should not be guided by hemoglobin concentration alone, but rather by assessment of a patient's overall clinical status and consideration of extenuating circumstances. **Important Notes:** * Further research is needed to determine the effect of various blood purification techniques on patient outcomes.
* Platelet transfusion thresholds in critically ill patients requiring low-bleeding risk invasive procedures are not clearly defined and are the subject of ongoing research.
* The use of platelet transfusions pre-procedure when antiplatelet agents have not been discontinued is not recommended.",Hb < 70 g/L is recommended in most critically ill patients.,3,3,20251106_110451,manual
Is PCC recommended for rapid reversal of warfarin in major bleeding?,"Based on the provided clinical guidelines and medical literature, the answer to the question ""Is PCC recommended for rapid reversal of warfarin in major bleeding?"" is as follows: **Recommendation:** Yes, PCC is recommended for rapid reversal of warfarin in major bleeding. **Evidence:** * According to the ASRA Guidelines 2025.md, when there is life-threatening bleeding, recombinant activated factor VIIa (rFVIIa), three-factor PCC, or four-factor PCC can be given. Activated rFVIIa and PCCs are better than FFP in reversing warfarin, and four-factor PCC appears to be more effective than three-factor PCC. [Source: ASRA Guidelines 2025.md]
* A study by Woo et al. (2014) compared the effectiveness of plasma, recombinant activated factor VII, and prothrombin complex concentrate in rapid warfarin reversal in the setting of intracranial hemorrhage. The results showed that prothrombin complex concentrate was more effective than recombinant activated factor VII in rapidly reversing warfarin. * Another study by Al-Majzoub et al. (2016) evaluated the effectiveness of four-factor prothrombin complex concentrate compared to three-factor prothrombin complex concentrate in warfarin reversal. The results showed that four-factor prothrombin complex concentrate was more effective than three-factor prothrombin complex concentrate in rapidly reversing warfarin. **Conclusion:** Based on the evidence from the ASRA Guidelines 2025.md and the studies by Woo et al. (2014) and Al-Majzoub et al. (2016), PCC is recommended for rapid reversal of warfarin in major bleeding. **Clinical Considerations:** * The choice of PCC (three-factor or four-factor) should be individualized based on the patient's specific circumstances and the severity of the bleeding.
* Patients with life-threatening bleeding should receive four-factor PCC, which appears to be more effective than three-factor PCC in rapidly reversing warfarin.
* Close monitoring of the patient's coagulation parameters and clinical status is essential to ensure optimal management of warfarin reversal. **References:** * ASRA Guidelines 2025.md
* WooCH, Patel N, Conell C, et al. Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg. 2014;81:110-115.
* Al-Majzoub O, Rybak E, Reardon DP, Krause P, Connors JM. Evaluation of warfarin reversal with 4-factor prothrombin complex concentrate compared to 3-factor prothrombin complex concentrate at a tertiary academic medical center. J Emerg Med. 2016;50:7-13.","Yes, PCC is indicated for rapid reversal of warfarin in life-threatening bleeding.",3,3,20251106_110451,manual
what are the independent risk factors for acute lung injury post thoracotomy?,"**Independent Risk Factors for Acute Lung Injury Post Thoracotomy** Acute Lung Injury (ALI) post thoracotomy is a multifactorial process involving various risk factors. Based on the provided clinical guidelines and medical literature, the following are the independent risk factors for ALI post thoracotomy: 1. **Preoperative Alcohol Abuse**: A history of preoperative alcohol abuse is identified as a risk factor for ALI post thoracotomy. [Source: step by step management of onelung ventilation CJA 2014.md]
2. **Low Intraoperative Tidal Volume**: Low intraoperative tidal volume ventilation with minimal Positive End-Expiratory Pressure (PEEP) is associated with increased mortality. [Source: Management-of-One-lung-Ventilation-Impact-of-Tidal-Volume-on-Complications-after-Thoracic-Surgery.md]
3. **High Plateau Pressure**: High plateau pressure (>30 cm H2O) is associated with increased risk of ALI. [Source: step by step management of onelung ventilation CJA 2014.md]
4. **Non-Lobar Atelectasis**: Non-lobar atelectasis generates inflammation and structural alveolar injury in the surrounding healthy tissue during mechanical ventilation. [Source: step by step management of onelung ventilation CJA 2014.md]
5. **Intraoperative Tidal Volume**: Intraoperative tidal volume is identified as a risk factor for respiratory failure after pneumonectomy. [Source: Management-of-One-lung-Ventilation-Impact-of-Tidal-Volume-on-Complications-after-Thoracic-Surgery.md]
6. **Atelectrauma**: Atelectrauma, which occurs due to the repetitive opening and closing of alveoli, is a risk factor for ALI. [Source: step by step management of onelung ventilation CJA 2014.md]
7. **Volutrauma**: Volutrauma, which occurs due to lung overdistension, is a risk factor for ALI. [Source: step by step management of onelung ventilation CJA 2014.md]
8. **Barotrauma**: Barotrauma, which occurs due to the direct effect of high pressure on the lungs, is a risk factor for ALI. [Source: step by step management of onelung ventilation CJA 2014.md]
9. **Biological Trauma**: Biological trauma, which occurs due to local inflammatory mediators and cytokines, is a risk factor for ALI. [Source: step by step management of onelung ventilation CJA 2014.md] **Conclusion** Acute Lung Injury post thoracotomy is a multifactorial process involving various risk factors. Understanding these risk factors is essential for the prevention and management of ALI. The use of evidence-based clinical guidelines and protocols, such as lung-protective ventilation strategies, can help mitigate these risks and improve patient outcomes. **References** [Source: Management-of-One-lung-Ventilation-Impact-of-Tidal-Volume-on-Complications-after-Thoracic-Surgery.md] [Source: step by step management of onelung ventilation CJA 2014.md] [Source: wk_3b_slinger_06_olv_management.md] **Disclaimer** This is a decision support tool and does not replace clinical judgment. All information should be verified against current clinical guidelines and protocols. In emergency situations or when in doubt, consult with senior colleagues or relevant specialists.","peak inspiratory pressure more than 40 cm H2o, plateau pressure more than 29 cm H20, excessive perioperative fluids, pneumonectomy, preoperative alcohol abuse",3,3,20251106_110451,manual
what are anesthetic considerations for patients with mitral regurgitation,"**Anesthetic Considerations for Patients with Mitral Regurgitation** Management of anesthesia for noncardiac surgery in patients with mitral regurgitation involves prevention and treatment of events that may further decrease cardiac output. The goal is to improve forward left ventricular stroke volume and decrease the regurgitant fraction. **Key Considerations:** * **Heart Rate:** Maintenance of a normal to slightly increased heart rate is recommended to prevent severe left ventricular volume overload. Bradycardia may result in severe left ventricular volume overload. [Source: 02_Stoelting.md]
* **Systemic Vascular Resistance:** Increases in systemic vascular resistance can cause decompensation of the left ventricle. A preoperative decrease in systemic vascular resistance caused by regional anesthesia may be beneficial in some patients. [Source: 02_Stoelting.md]
* **Cardiac Output:** Cardiac output can be maintained or improved with modest increases in heart rate and modest decreases in systemic vascular resistance. [Source: 02_Stoelting.md]
* **Monitoring:** Invasive monitoring is recommended in the presence of severe mitral regurgitation to detect the adequacy of cardiac output and the hemodynamic response to anesthetic and vasodilating drugs. [Source: 02_Stoelting.md]
* **Transesophageal Echocardiography:** Transesophageal echocardiography is a useful technique for monitoring mitral valve and left ventricular function during major surgery. [Source: 02_Stoelting.md]
* **Induction of Anesthesia:** Induction of anesthesia can be achieved with an intravenous induction drug. Dosing should be adjusted to prevent an increase in systemic vascular resistance or a decrease in heart rate, as both of these hemodynamic changes reduce cardiac output. [Source: 02_Stoelting.md]
* **Muscle Relaxants:** Selection of a muscle relaxant should follow the same principles as induction of anesthesia, with consideration of the potential effects on heart rate and systemic vascular resistance. Pancuronium produces a modest increase in heart rate, which can contribute to maintenance of forward left ventricular stroke volume. [Source: 02_Stoelting.md] **Pharmacological Considerations:** * **Vasodilators:** Although vasodilators are useful in the medical management of acute mitral regurgitation, there is no apparent benefit to long-term use of these drugs in asymptomatic patients with chronic mitral regurgitation. For symptomatic patients, angiotensin-converting enzyme inhibitors or β-blockers (particularly carvedilol) and biventricular pacing have all been shown to decrease functional mitral regurgitation and improve symptoms and exercise tolerance. [Source: 02_Stoelting.md] **Other Considerations:** * **Mitral Valve Prolapse:** Mitral valve prolapse (MVP) is a condition characterized by the prolapse of one or both mitral leaflets into the left atrium during systole with or without mitral regurgitation. MVP is associated with a risk of complications such as cerebral embolic events, infective endocarditis, severe mitral regurgitation requiring surgery, dysrhythmias, and sudden death. [Source: 02_Stoelting.md] **Key References:** [Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md]
[Source: 02_Stoelting.md] **Important Safety Considerations:** * Patients with severe mitral regurgitation may require invasive monitoring and careful management of anesthesia to prevent cardiac decompensation.
* The use of vasodilators in asymptomatic patients with chronic mitral regurgitation is not recommended.
* Patients with mitral valve prolapse should be monitored for potential complications and managed accordingly.","prevent bradycardia, prevent increases in systemic vascular resistance, minimize drug induced myocardial depression, and ",3,3,20251106_110451,manual
"following an accidental dural puncture with an epidural needle, what is the incidence of post dural puncture headache (PDPH)?","Based on the provided context, the incidence of post-dural puncture headache (PDPH) following an accidental dural puncture with an epidural needle is as follows: - The incidence of PDPH is approximately 1% following any neuraxial procedure [Source: 2025_CAS_Revised_Guidelines.md]
- However, the incidence is greater than 50% following accidental dural puncture with a 16-18G epidural needle [Source: 2025_CAS_Revised_Guidelines.md] It is essential to note that the size of the dural puncture is an important risk factor for PDPH. The use of pencil-point needles (e.g., Whitacre, Sprotte, Pencan, and Gertie-Marx) decreases the risk of PDPH compared with cutting needles (e.g., Quincke) of the same size [Source: 2025_CAS_Revised_Guidelines.md] The management of PDPH includes conservative treatments such as a combination of bed rest and hydration, oral analgesics, and a single 300-mg dose of oral caffeine [Source: 2025_CAS_Revised_Guidelines.md]. In cases where these treatments are ineffective, an epidural blood patch may be considered [Source: Anesthesia Notes.md]. The incidence of complications from epidural blood patch, including back pain, neck pain, radicular pain, cauda equine syndrome, paraparesis, meningitis, aseptic meningeal irritation, and abscess, increases with increased volume [Source: Anesthesia Notes.md]. The success rates for epidural blood patch are approximately 75% for the first patch and 80% for the second patch [Source: Anesthesia Notes.md]. Headache symptoms resolve almost immediately after the procedure, and possible mechanisms include an increase in CSF pressure and cerebral vasoconstriction [Source: Anesthesia Notes.md]. It is worth noting that the timing of epidural blood patch is controversial, and prophylactic blood patch may or may not be effective [Source: Anesthesia Notes.md]. However, epidurally administered fibrin glue has been shown to be an effective alternative to blood administration [Source: Anesthesia Notes.md].",greater than 50%,3,3,20251106_110451,manual
